REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
REGENERON PHARMACEUTICALS, INC. (REGN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $1.42 billion as of 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2018-05-03
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $1.42B.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $1.04B.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $820.87M.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $817.98M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2018-03-31 | $1.42B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $1.04B 10-Q · filed 2018-05-03 |
| 2017-09-30 | $820.87M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $817.98M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $894.53M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $883.95M 10-K · filed 2018-02-08 |
| 2016-09-30 | $436.43M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $94.97M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $151.83M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $731.33M 10-K · filed 2017-02-09 |
| 2015-09-30 | $395.89M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $446.87M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $140.66M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $426.94M 10-K · filed 2016-02-11 |
| 2014-09-30 | $355.74M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $164.18M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $286.34M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $239.81M 10-K · filed 2015-02-12 |
| 2013-03-31 | $146.95M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $63.44M 10-K · filed 2014-02-13 |
| 2012-06-30 | $118.89M 10-Q · filed 2012-07-25 |
| 2012-03-31 | $279.23M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $111.77M 10-K · filed 2013-02-15 |
| 2011-09-30 | $70.31M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $30.34M 10-Q · filed 2011-07-28 |
| 2010-12-31 | $369.21M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |